glp 1 vs sglt2 Cardiorenal Protection: Potential of Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes | Diabetes Therapy GLP-1 Receptor Agonists and SGLT2

Yu H, Rimbert A, Palmer AE, Toyohara T, Xia Y, Xia F, et al

Diabetes is a complex disease that requires not only adherence to medications (including insulin regimens and oral drugs) but also to diet, physical exercise and home glucose monitoring, among others

While NZ doesnt yet fund metformin for MS, the MACSiMiSE-BRAIN trial overseas is exploring its neuroprotective potential in progressive MS

11,242,243 Long-term human studies demonstrated that chronic DPP-IV inhibition did not significantly mediate any cardiovascular (CV) benefits

We also found that JWU-A021 failed to stimulate an increase of the [Ca 2+ ] i when the extracellular [Ca 2+ ] was lowered from 2.6 mM to 100 nM (Fig

Youll also find tips for staying consistent and managing your routine, along with guidance on when adjustments may be necessary